November 5th, 2018

// LANCORA™ (ivabradine) now covered by the Ontario Public Drug Program

CNW Group Ltd

LANCORA™ (ivabradine) now covered by the Ontario Public Drug Program and British Columbia PharmaCare for patients suffering from chronic heart failure

LAVAL, QC, Nov. 5, 2018 /CNW Telbec/ – Servier Canada Inc. is pleased to announce that following Quebec and Saskatchewan, LANCORA™ is now covered by the Ontario Public Drug Program and British Columbia PharmaCare for patients suffering from chronic heart failure.

LANCORA™ can be prescribed and reimbursed for the treatment of stable chronic heart failure with reduced left ventricular ejection fraction (LVEF) (≤35%) in adult patients with New York Heart Association (NYHA) classes II or III who are in sinus rhythm with a resting heart rate ≥ 77 beats per minute (bpm), to reduce the incidence of cardiovascular mortality and hospitalizations for worsening heart failure, administered in combination with standard chronic heart failure therapies. See individual formulary listings for province specific criteriai,ii.

Over 600 000 Canadians are living with heart failure and 50 000 are diagnosed with the condition every year. Heart failure is a major cause of illness and disability, long and frequent hospital stays and premature death. Heart failure is a complex and incurable condition, resulting in the heart not being able to pump sufficient blood to meet the body’s demandsiii.

“Increasing access to innovative drugs that not only save lives but also reduce the risk of hospitalization is a major advancement for heart failure patients but also their families and caregivers” said Dr Peter Liu, Chief Scientific Officer and Vice President of Research at the University of Ottawa Heart Institute.

“We are very pleased that patients in Ontario covered by the Ontario Public Drug Program and patients in BC covered by PharmaCare will now have access to the benefits of LANCORA™. LANCORA™ has already been included in the Drug Benefit plans of Quebec and Saskatchewan, and we continue to work with the other provinces so that across Canada, heart failure patients will have equal access to LANCORA™” said Frederic Fasano, Chief Executive Officer of Servier Canada. “Servier is committed to therapeutic progress to serve patient’s needs, all of our activities are centered on this objective.”

About LANCORA™
LANCORA™ (ivabradine) is indicated for the treatment of stable chronic heart failure with reduced left ventricular ejection fraction (≤ 35%) in adult patients with NYHA Classes II or III who are in sinus rhythm with a resting heart rate ≥ 77 beats per minute, to reduce the incidence of cardiovascular mortality and hospitalisations for worsening heart failure.iv

About Servier Canada
Servier Canada Inc. is an affiliate of the independent French Servier Group. Our mission is to provide the Canadian medical community and its patients with innovative therapeutic solutions. As such, Servier Canada collaborates with various players in the healthcare system including researchers, entrepreneurs and innovators. In addition to these research partners, the Canadian International Center for Therapeutic Research (ICTR) is dedicated to clinical development with more than 50 studies conducted throughout Canada over the last 10 years.

More information is available at www.servier.ca

____________________
i. https://www.formulary.health.gov.on.ca/formulary/
ii. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/special-authority#Druglist
iii. The Burden of Heart Failure: 2016 report on the health of Canadians. https://www.heartandstroke.ca accessed July 18th, 2018
iv. LANCORA Product Monograph, May 2018

 

SOURCE Servier Canada Inc.

Leave a Reply

Your email address will not be published. Required fields are marked *

TRAIN IT RIGHT NEWSLETTER

Sign Up and get a free 7 day Train it Right HIIT Program!

Top